Table 1.
Baseline demographic and clinical characteristics of study participants
| COVID-19 patients (n = 76) | Healthy controls (n = 44) | p-value | |
|---|---|---|---|
| Age (years) | 37.5 ± 9.6 (18–58) | 38.8 ± 9.5 (20–57) | 0.70 |
| Gender (female/male) | 47/29 | 25/19 | 0.70 |
| Education (years) | 14.2 ± 3.6 (5–18) | 14.7 ± 3.1 (5–18) | 0.66 |
| Time to electrophysiological evaluation after COVID-19 infection (months) | 4.4 ± 2.2 (1–12) | - | |
| Severity of COVID-19 pneumonia | 27 (35.5%) | - | |
| Mild | 8 | ||
| Moderate | 16 | ||
| Severe | 3 | ||
| COVID-19 hospitalization | 6 (7.9%) | ||
| COVID-19 treatment | |||
| Favipiravir | 55 (72.4%) | ||
| Acetyl salicylic acid | 17 (22.4%) | ||
| Hydroxychloroquine | 10 (13.1%) | ||
| Vitamin C | 7 (9.2%) | ||
| Enoxaparin (SC) | 7 (9.2%) | ||
| Ampiric antibiotics | 3 (3.9%) | ||
| Oral prednisone | 1 (1.3%) | ||
Demographic data and clinical features of COVID-19 patients and controls are shown above
A p-value < 0.05 is significant